Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

Eligibility Criteria

• * Are between ≥ 18 years and ≤ 85 years at the signing of informed consent
• * Have a history of chronic HFrEF, defined as requiring treatment for HF for a minimum of 3 months prior to screening
• * Are receiving oral loop diuretics
• * Have a left ventricular ejection fraction (LVEF) \< 30% measured within the prior 6 months
• * Are currently hospitalized with the primary reason of HF, or had an HF event within 6 months prior to screening
• * Are established on regional standard-of-care HF therapies for at least 30 days prior to screening
• * Systolic blood pressure ≤ 130 mmHg and diastolic blood pressure ≤ 90 mmHg
• * Have elevated natriuretic peptide levels (B-type natriuretic peptide \[BNP\] or N-terminal prohormone of B-type natriuretic peptide \[NT-proBNP\]) at screening:
• 1. Patients without AFF on the screening electrocardiogram (ECG): BNP ≥ 300 pg/mL or NT-proBNP ≥ 1,000 pg/mL
• 2. Patients with AFF on the screening ECG: BNP ≥ 900 pg/mL or NT-proBNP ≥ 3,000 pg/mL
• * Have AFF on the screening ECG and are currently taking digoxin
• * Have had acute coronary syndrome, cardiac surgery, valve surgery, any coronary revascularization, and/or cardiac resynchronization therapy within 3 months of screening
• * Are admitted to a long-term care facility or hospice
• * Have a projected survival of \< 12 months due to non-cardiovascular causes based on clinical judgment
• * Are receiving intravenous inotropes or intravenous vasopressors ≤ 3 days prior to screening
• * Are receiving mechanical hemodynamic support or mechanical ventilation ≤ 7 days prior to screening
• * Are receiving intravenous diuretics, intravenous vasodilators, or supplemental oxygen therapy ≤ 12 hours prior to screening
• * Have an estimated glomerular filtration rate (eGFR) \< 20 mL/min/1.73m2 or receiving dialysis at screening
• * Have previously had a solid organ transplant
• * Are receiving treatment in another investigational device or drug study or are within 30 days of ending such investigational treatment at screening
• * Have previously received omecamtiv mecarbil
• * Are pregnant or planning pregnancy during the study period, or planning to breastfeed during treatment with IP or within 5 days after the end of treatment with IP